TRI Pointe Homes Inc. (NYSE: TPH) has agreed to acquire the homebuilding and real estate subsidiary of Weyerhaeuser Co. (NYSE: WY) for approximately $2.7 billion.www.TRIPointeHomes.com
Warburg Pincus has sold its entire 33.9% stake in Transpacific Industries Group (ASX: TPI), an Australian waste management company, according to the Australian Financial Review.www.warburgpincus.com
The Carlyle Group has completed its previously-announced acquisition of Metropolitan Real Estate Equity Management, a global manager of real estate funds-of-funds with more than $2.6 billion in capital commitments. No financial terms were disclosed for the deal, which is expected to close in November. www.carlyle.com
Roche (SWX: ROG) has signed an exclusive global licensing deal with Switzerland-based Polyphor to further develop and commercialize a Polyphor antibiotic that treats certain “superbug” hospital infections. The deal could be valued at upwards of $548 million. Polyphore backers include BioMedPartners, Core Capital Partners and Novartis Venture Funds. www.roche.com
AutoGenomics Inc., a Vista, Calif.-based maker of molecular diagnostics systems, has withdrawn IPO registration. It did not provide an explanation. The company had planned to offer 6 million shares at between $9 and $11 per share, and to trade on the Nasdaq under ticker symbol AGMX. Leerink Swann was serving as lead underwriter. This is the second time that AutoGenomics has withdrawn an IPO registration. www.autogenomics.com
Twitter has increased its IPO price range from $17-$20 per share to $23-$25 per share. It still plans to offer 70 million shares, and trade on the NYSE under ticker symbol TWTR. www.twitter.com
DTLR Holding (a.k.a. Down Town Locker Room), a Hanover, Md.-based retailer of “street-inspired” footwear, apparel and accessories, has filed for a $75 million IPO. It plans to trade on the Nasdaq under ticker symbol DTLR, with Baird and Piper Jaffray serving as lead underwriters. The company reports $5 million of net income on $181 million in revenue for the year ending February 2, 2013. Shareholders include Bruckmann, Rosser, Sherrill & Co. (88.19% of common stock) and Golub Capital (6.9%). www.dtlr.com
J.G. Wentworth, a Radnor, Penn.-based buyer of deferred payments and illiquid financial assets, has set its IPO terms to 12.2 million shares being offered at between $19 and $22 per share. It plans to trade on the NYSE under ticker symbol JGW, with Barclays and Credit Suisse serving as lead underwriters. The company reports $128 million in net income on around $484 million in revenue for the 12 months ending June 30, 2013. J.G. Wentworth is owned by JLL Partners. www.jgwentworth.com
Relypsa Inc., a Redwood City, Calif.-based developer of non-absorbed polymeric drugs, has set its IPO terms to 6.85 million shares being offered at between $16 and $19 per share. It would have an initial market cap of approximately $502 million, were it to price in the middle of its range. The pre-revenue company plans to trade on the Nasdaq, with Morgan Stanley and BoA Merrill Lynch serving as lead underwriters. Relypsa has raised over $180 million in VC funding from OrbiMed Advisors (43.3% pre-IPO stake), 5AM Ventures (22.3%), Delphi Ventures (11.8%), New Leaf Ventures (10.4%), Sprout Capital (9.7%) and Sibling Capital (5.3%). www.relypsa.com
Tandem Diabetes Care, a San Diego-based maker of medical devices for treating diabetes, has set its IPO terms to 7.14 million shares being offered at between $13 and $15 per share. It would have an initial market cap of approximately $287 million, were it to price in the middle of its range. The company plans to trade on the Nasdaq under ticker symbol TNDM, with BoA Merrill Lynch and Piper Jaffray serving as lead underwriters. It has raised around $88 million in VC funding from firms like Delphi Ventures (26.91% pre-IPO stake), Domain Associates (26.22%), TPG Biotechnology Partners (20.30%), HLM Venture Partners (11.43%) and Kearny Venture Partners (6.4%).www.tandemdiabetes.com
Xencor Inc., a Monrovia, Calif.-based developer of engineered monoclonal antibodies, has set its IPO terms to 5 million shares being offered at between $14 and $16 per share. It would have an initial market cap of approximately $325 million, were it to price in the middle of its range. The company plans to trade on the Nasdaq under ticker symbol XNCR, with Credit Suisse and Leerink Swann serving as lead underwriters. Shareholders include MedImmune Ventures (8.2% pre-IPO stake) and HealthCare Ventures (6.4%). www.xencor.com
Zulily, a Seattle-based ecommerce company focused on clothing and products for babies and children, has set its IPO terms to 11.5 million shares being offered at between $16 and $18 per share. It would have a fully-diluted market cap of approximately $2.2 billion, were it to price in the middle of its range. The company plans to trade on the Nasdaq under ticker symbol ZU, with Goldman Sachs, BoA Merrill Lynch and Citigroup serving as lead underwriters. It reports $2.4 million in net income on $272 million in revenue for the first half of 2013, compared to a $6 million net loss on $127 million in revenue for the year-earlier period. Zulily has raised nearly $140 million in VC funding from Maveron (23.6% pre-IPO stake), August Capital (7.5%) and Andreessen Horowitz (7.3%). www.zulily.com
Sign up for Dan’s daily email newsletter on deals and deal-makers: GetTermSheet.com
